179 related articles for article (PubMed ID: 15320898)
1. Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease.
Garman RD; Munroe K; Richards SM
Clin Exp Immunol; 2004 Sep; 137(3):496-502. PubMed ID: 15320898
[TBL] [Abstract][Full Text] [Related]
2. Antibody Epitope of Human α-Galactosidase A Revealed by Affinity Mass Spectrometry: A Basis for Reversing Immunoreactivity in Enzyme Replacement Therapy of Fabry Disease.
Kukacka Z; Iurascu M; Lupu L; Rusche H; Murphy M; Altamore L; Borri F; Maeser S; Papini AM; Hennermann J; Przybylski M
ChemMedChem; 2018 May; 13(9):909-915. PubMed ID: 29473701
[TBL] [Abstract][Full Text] [Related]
3. Anti-BlyS antibody reduces the immune reaction against enzyme and enhances the efficacy of enzyme replacement therapy in Fabry disease model mice.
Sato Y; Ida H; Ohashi T
Clin Immunol; 2017 May; 178():56-63. PubMed ID: 28161408
[TBL] [Abstract][Full Text] [Related]
4. Detailed epitope mapping of neutralizing anti-drug antibodies against recombinant α-galactosidase A in patients with Fabry disease.
Scharnetzki D; Stappers F; Lenders M; Brand E
Mol Genet Metab; 2020; 131(1-2):229-234. PubMed ID: 32888778
[TBL] [Abstract][Full Text] [Related]
5. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.
Linthorst GE; Hollak CE; Donker-Koopman WE; Strijland A; Aerts JM
Kidney Int; 2004 Oct; 66(4):1589-95. PubMed ID: 15458455
[TBL] [Abstract][Full Text] [Related]
6. AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice.
Ziegler RJ; Lonning SM; Armentano D; Li C; Souza DW; Cherry M; Ford C; Barbon CM; Desnick RJ; Gao G; Wilson JM; Peluso R; Godwin S; Carter BJ; Gregory RJ; Wadsworth SC; Cheng SH
Mol Ther; 2004 Feb; 9(2):231-40. PubMed ID: 14759807
[TBL] [Abstract][Full Text] [Related]
7. Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment.
van der Veen SJ; van Kuilenburg ABP; Hollak CEM; Kaijen PHP; Voorberg J; Langeveld M
Mol Genet Metab; 2019 Feb; 126(2):162-168. PubMed ID: 30473480
[TBL] [Abstract][Full Text] [Related]
8. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease.
Ohashi T; Iizuka S; Ida H; Eto Y
Mol Genet Metab; 2008 Jul; 94(3):313-8. PubMed ID: 18456533
[TBL] [Abstract][Full Text] [Related]
9. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
[TBL] [Abstract][Full Text] [Related]
10. Transient siRNA-mediated attenuation of liver expression from an alpha-galactosidase A plasmid reduces subsequent humoral immune responses to the transgene product in mice.
Chu Q; Joseph M; Przybylska M; Yew NS; Scheule RK
Mol Ther; 2005 Aug; 12(2):264-73. PubMed ID: 15946902
[TBL] [Abstract][Full Text] [Related]
11. Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.
Wilcox WR; Linthorst GE; Germain DP; Feldt-Rasmussen U; Waldek S; Richards SM; Beitner-Johnson D; Cizmarik M; Cole JA; Kingma W; Warnock DG
Mol Genet Metab; 2012 Mar; 105(3):443-9. PubMed ID: 22227322
[TBL] [Abstract][Full Text] [Related]
12. The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease.
Limgala RP; Fikry J; Veligatla V; Goker-Alpan O
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003611
[TBL] [Abstract][Full Text] [Related]
13. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
Lenders M; Neußer LP; Rudnicki M; Nordbeck P; Canaan-Kühl S; Nowak A; Cybulla M; Schmitz B; Lukas J; Wanner C; Brand SM; Brand E
J Am Soc Nephrol; 2018 Dec; 29(12):2879-2889. PubMed ID: 30385651
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease, enzyme replacement therapy and the significance of antibody responses.
Deegan PB
J Inherit Metab Dis; 2012 Mar; 35(2):227-43. PubMed ID: 22037707
[TBL] [Abstract][Full Text] [Related]
15. Cellular and tissue distribution of intravenously administered agalsidase alfa.
Murray GJ; Anver MR; Kennedy MA; Quirk JM; Schiffmann R
Mol Genet Metab; 2007 Mar; 90(3):307-12. PubMed ID: 17188539
[TBL] [Abstract][Full Text] [Related]
16. Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease.
van der Veen SJ; Vlietstra WJ; van Dussen L; van Kuilenburg ABP; Dijkgraaf MGW; Lenders M; Brand E; Wanner C; Hughes D; Elliott PM; Hollak CEM; Langeveld M
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806627
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.
Vedder AC; Breunig F; Donker-Koopman WE; Mills K; Young E; Winchester B; Ten Berge IJ; Groener JE; Aerts JM; Wanner C; Hollak CE
Mol Genet Metab; 2008 Jul; 94(3):319-25. PubMed ID: 18424138
[TBL] [Abstract][Full Text] [Related]
18. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease.
Kizhner T; Azulay Y; Hainrichson M; Tekoah Y; Arvatz G; Shulman A; Ruderfer I; Aviezer D; Shaaltiel Y
Mol Genet Metab; 2015 Feb; 114(2):259-67. PubMed ID: 25155442
[TBL] [Abstract][Full Text] [Related]
20. [Current status and future prospect of enzyme replacement therapy for Fabry disease].
Ohashi T
Rinsho Shinkeigaku; 2019 Jun; 59(6):335-338. PubMed ID: 31142708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
